Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Daniel van der Lelie
AddedApr 28, 2026
UpdatedMay 31, 2026
Daniel van der Lelie

Daniel van der Lelie

Chief Scientific Officer, Gusto Global

LinkedIn

Daniel van der Lelie's Career

Gusto Global
Gusto Global

Morrisville, NC, US

Chief Scientific Officer· C-Suite · Research & Development

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Daniel van der Lelie's Career

Gusto Global
Gusto Global
Seed$5.5M2015Morrisville, NC, US
Chief Scientific Officer· C-Suite · Research & Development

Recent news

Gusto Global and Crohn's & Colitis Foundation Expand Partnership to Advance Prognostic and Therapeutic Technologies for IBDBusiness Wire · 2023
New $1.85M in funding is good for the gut: Gusto GlobalWRAL TechWire · 2022
Healthy Microbiome Designed by Gusto Global Shows Promise to Radically Change Treatment for Inflammatory DiseasesBioSpace · 2021

Leadership at Gusto Global

Mark SpizerMark SpizerCOO
John FennebresqueJohn FennebresqueManaging Director
Joshua KorzenikJoshua KorzenikScientific Advisor
Balfour SartorBalfour SartorScientific Advisor
Christopher HenryChristopher HenryScientific Advisor
Logan LevyLogan LevyDirector of Business Development

Similar to Gusto Global

Persephone BiosciencesPersephone BiosciencesSan Diego, CA, USBiotherapeutics, Drugsest. 2017Persephone BiosciencesSan Diego, CA, US · est. 2017

Persephone Biosciences crafts microbial drugs to fight cancer using AI and gut microbiome analysis.

Seed · $15.2M17
BioPlxBioPlxBoulder, CO, USBiotherapeuticsest. 2015BioPlxBoulder, CO, US · est. 2015

BioPlx, an advanced microbiome company, develops non-antibiotic solutions to control infectious diseases using live bio-therapeutic products.

Pre-Seed · $2.7M30

Daniel van der Lelie's Similar Executives & Operators

Hien KaplanHien KaplanChief Scientist · Function of BeautyFlorian SolzbacherFlorian SolzbacherChief Scientific Officer · Blackrock NeurotechNeema MoravejiNeema MoravejiChief Scientist · Spire HealthJeff Hester, PhDJeff Hester, PhDChief Scientific Officer · PathologyWatchLotan ChorevLotan ChorevCo-Founder & VP R&D · NucleaiJonathan FrankleJonathan FrankleChief Scientist · MosaicMLDave GustafsonDave GustafsonCo-founder & VP, Hardware · RhombusAnup SinghAnup SinghChief Scientific Officer · InnaMed

People Similar to Daniel van der Lelie

Safiyh TaghaviSafiyh TaghaviCTO · Gusto GlobalDaniel NewmanDaniel NewmanCEO · Global WorksPeter SwanPeter SwanCEO · GustKelly RuigrokKelly RuigrokFounder & CEO · GsesLevon Paul ThoroseLevon Paul ThoroseCEO · Global Innovations